F
Fabio A.B. Schutz
Researcher at Harvard University
Publications - 86
Citations - 9410
Fabio A.B. Schutz is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 29, co-authored 81 publications receiving 7604 citations. Previous affiliations of Fabio A.B. Schutz include Niigata University & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Second brazilian consensus on the treatment of advanced prostate cancer: a SBOC-SBU-SBRT panel review
Andre Deeke Sasse,Rodolfo Borges dos Reis,Lucas Mendes Nogueira,Fernando C. Maluf,Daniel Herchenhorn,Oren Smaletz,Volney Soares Lima,Fabio A.B. Schutz,Diogo Assed Bastos,Evanius Garcia Wiermann,Igor Alexandre Protzner Morbeck,Leonardo Fontes Jardim,Vinicius Carrera Souza,Icaro Thiago de Carvalho,Elton Trigo Teixeira Leite,Archimedes Nardozza,Antonio Carlos Lima Pompeo,Francisco Flávio Horta Bretas,Marcos Lima de Oliveira Leal,Marcus Vinicius Sadi,José Ricardo Tuma da Ponte,Gustavo F. Carvalhal +21 more
TL;DR: The aim of this consensus is to align different opinions and interpretations of the medical literature in a practical and patient-oriented approach to support the clinical decisions of physicians and other health professionals involved in the care of patients with prostate cancer.
Journal ArticleDOI
Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective.
J. P. Sade,Carlos Alberto Vargas Báez,Martin Greco,Carlos Humberto Martínez,Miguel Ángel Álvarez Avitia,Carlos Palazzo,Narciso Hernández Toriz,Patricia Isabel Bernal Trujillo,Diogo Assed Bastos,Fabio A.B. Schutz,Santiago Bella,Lucas Nogueira,Neal D. Shore +12 more
TL;DR: Recommendations were provided for the use of taxane-based chemotherapies, androgen receptor axis-targeted agents and targeted alpha therapy, for patients in Latin America, in the context of country-level variable access to approved agents and technologies for treatment monitoring.
Journal ArticleDOI
A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415).
Fernando C. Maluf,Fabio A.B. Schutz,Eduardo Cronemberger,Murilo Luz,Suelen Patrícia dos Santos Martins,David Queiroz Borges Muniz,Diogo Assed Bastos,Flavio Mavignier Carcano,Oren Smaletz,Andrey Soares,Fabio A. Peixoto,Andrea J. Pereira de Santana Gomes,Felipe Melo Cruz,Fabio Franke,Daniel Herchenhorn,Telma Santos,Vanessa Carvalho Fabricio,Rosemarie Gidekel,Gustavo Werutsky,Rafaela Gomes de Jesus,Vinicius Carrera Souza,Andre P. Fay +21 more
TL;DR: The LACOG 0415 trial as mentioned in this paper showed that ADT-free alternatives provide a high PSA response in advanced CSPC, although the APA arm did not reach the expected rate of PSA of ≤ 0.2 ng/mL at week 25.
Journal ArticleDOI
Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk.
Thomas Powles,Robert J. Motzer,Laurence Albiges,Cristina Sáez,Fabio A.B. Schutz,Daniel Y.C. Heng,Christine Chevreau,Ravindran Kanesvaran,Howard Gurney,Fong-xia Wang,Fabio D. Mataveli,Yu-Lin Chang,Maximiliano van Kooten Losio,Toni K. Choueiri +13 more
TL;DR: Choueiri et al. as mentioned in this paper found that C+N+I significantly improved progression-free survival compared with N+I in first-line aRCC of IMDC intermediate or poor risk.
Journal ArticleDOI
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
Toni K. Choueiri,Thomas Powles,Laurence Albiges,Mauricio Burotto,Cezary Szczylik,B. Zurawski,Eduardo Yanez Ruiz,Marco Maruzzo,Luis Fein,Fabio A.B. Schutz,Daniel Y.C. Heng,Fong-xia Wang,Fabio D. Mataveli,Yu-Lin Chang,Maximiliano van Kooten Losio,Cristina Sáez,Robert J. Motzer +16 more
TL;DR: In this paper , the efficacy and safety of treatment with cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal-cell carcinoma are unknown.